Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SRA-333 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SRA-333 | DRUG | - |
Inclusion Criteria: * Diagnosis of probable AD according to the NINCDS-ADRDA criteria. * Men and postmenopausal or surgically sterile women aged from 50 to 85 inclusive. * Able to give informed consent. Patient's caregiver must consent to participate in the study. Exclusion Criteria: * Significan...
Top 20 of 24 competitors
SRA-333 is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is being developed by Pfizer, Inc. for use in patients with mild to moderate Alzheimer's Disease, as evaluated in a clinical trial conducted in the United States.
The specific molecular target of SRA-333 has not been disclosed. It is a small molecule being investigated for its potential effects in Alzheimer's Disease, but the precise biological mechanism of action has not been publicly detailed.
SRA-333 is being developed by Pfizer, Inc., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical research to evaluate the safety and efficacy of SRA-333 in patients with Alzheimer's Disease.
SRA-333 is in Phase 2 clinical development. It has completed a Phase 2 trial (NCT00151333) that evaluated the drug in patients with mild to moderate Alzheimer's Disease. The drug is still investigational and has not been approved by regulatory authorities.
SRA-333 has been studied in one clinical trial, NCT00151333, titled 'Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)'. This Phase 2 trial was completed and enrolled 16 participants in the United States. The trial was randomized and double-blind, but did not use a control group.
No alternative names for SRA-333 have been disclosed. The drug is identified solely by its code name SRA-333 in clinical trial records and by its developer, Pfizer, Inc.